THE INCIDENCE, MORTALITY, AND SURVIVAL OF MALIGNANT CHONDROSARCOMA IN THE UNITED STATES: A SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER) 2000-2023 DATABASE ANALYSIS
Author(s)
Vlad Zah, PhD, Filip Stanicic, PhD (c), Dimitrije Grbic, PhD (c).
Health Economist, ZRx Outcomes Research, Inc., Mississauga, ON, Canada.
Health Economist, ZRx Outcomes Research, Inc., Mississauga, ON, Canada.
OBJECTIVES: To explore the disease burden of chondrosarcoma in the US using the most recent Surveillance, Epidemiology, and End Results (SEER) database updated in April 2026.
METHODS: Data from 21 US cancer registries (2000-2023) were analyzed using SEER*Stat. The target population included malignant chondrosarcoma patients. Outcomes were crude incidence and mortality rates (per 100,000 population) and survival rates (percentages at 1-year and 5-year endpoints).
RESULTS: A total of 11,162 US patients with malignant chondrosarcoma were identified. Most patients had an unspecified chondrosarcoma subtype (72.4%), with myxoid chondrosarcoma (13.4%) as the most prevalent known type. Patients were mostly 20-64 years old (64.9%), males (55.1%), Non-Hispanic Whites (70.1%), from metropolitan counties (88.8%), and had an annual household income (AHI) of $65,000-$90,000 (48.2%). The incidence rate of chondrosarcoma was 0.326, with unspecified (0.236) and myxoid (0.044) types as the most common. Among population subgroups, higher rates were reported for ≥65-year-olds (0.793), males (0.364), Non-Hispanic Whites (0.421), and ≥$120,000 AHI (0.402). Trends showed an increasing incidence of dedifferentiated chondrosarcoma (2.5 annual percent change [APC], p<0.050) and a decreasing incidence of myxoid chondrosarcoma (-1.4 APC, p<0.050). The chondrosarcoma mortality rate was 0.123, with the highest mortality among patients with unspecified type (0.080). Higher rates were observed among males (0.148), Non-Hispanic Whites (0.170), and those with <$40,000 AHI (0.160). A significant trend was reported for the unspecified and myxoid chondrosarcoma subtypes with increasing values over the years (4.9 and 2.7 APC, respectively; both p<0.050). The highest 1-year survival was observed in grade 1 (98.8%) and the lowest in dedifferentiated chondrosarcoma (54.7%). The highest 5-year survival was noted in juxtacortical (93.5%), and the lowest in dedifferentiated (24.9%).
CONCLUSIONS: The study findings showed an alarming chondrosarcoma burden, with the highest proportion of undetermined chondrosarcoma subtype. Increasing incidence and mortality trends emphasize the need for novel treatment options.
METHODS: Data from 21 US cancer registries (2000-2023) were analyzed using SEER*Stat. The target population included malignant chondrosarcoma patients. Outcomes were crude incidence and mortality rates (per 100,000 population) and survival rates (percentages at 1-year and 5-year endpoints).
RESULTS: A total of 11,162 US patients with malignant chondrosarcoma were identified. Most patients had an unspecified chondrosarcoma subtype (72.4%), with myxoid chondrosarcoma (13.4%) as the most prevalent known type. Patients were mostly 20-64 years old (64.9%), males (55.1%), Non-Hispanic Whites (70.1%), from metropolitan counties (88.8%), and had an annual household income (AHI) of $65,000-$90,000 (48.2%). The incidence rate of chondrosarcoma was 0.326, with unspecified (0.236) and myxoid (0.044) types as the most common. Among population subgroups, higher rates were reported for ≥65-year-olds (0.793), males (0.364), Non-Hispanic Whites (0.421), and ≥$120,000 AHI (0.402). Trends showed an increasing incidence of dedifferentiated chondrosarcoma (2.5 annual percent change [APC], p<0.050) and a decreasing incidence of myxoid chondrosarcoma (-1.4 APC, p<0.050). The chondrosarcoma mortality rate was 0.123, with the highest mortality among patients with unspecified type (0.080). Higher rates were observed among males (0.148), Non-Hispanic Whites (0.170), and those with <$40,000 AHI (0.160). A significant trend was reported for the unspecified and myxoid chondrosarcoma subtypes with increasing values over the years (4.9 and 2.7 APC, respectively; both p<0.050). The highest 1-year survival was observed in grade 1 (98.8%) and the lowest in dedifferentiated chondrosarcoma (54.7%). The highest 5-year survival was noted in juxtacortical (93.5%), and the lowest in dedifferentiated (24.9%).
CONCLUSIONS: The study findings showed an alarming chondrosarcoma burden, with the highest proportion of undetermined chondrosarcoma subtype. Increasing incidence and mortality trends emphasize the need for novel treatment options.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EPH31
Topic
Clinical Outcomes, Epidemiology & Public Health, Real World Data & Information Systems
Disease
Musculoskeletal Disorders (Arthritis, Bone Disorders, Osteoporosis, Other Musculoskeletal), No Additional Disease & Conditions/Specialized Treatment Areas, Oncology, Rare & Orphan Diseases